Optical coherence tomography-guided ranibizumab injection for cystoid macular edema in well-controlled uveitis: Twelve-month outcomes

Ashvini K. Reddy, Mariana Cabrera, Steven Yeh, Janet L Davis, Thomas A Albini

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Purpose: To determine whether serial ranibizumab injections are effective in the treatment of cystoid macular edema in patients with chronic controlled noninfectious uveitis.

Methods: Five eyes of 5 patients were included in a prospective noncomparative therapeutic trial. They received intravitreal injections of ranibizumab at Day 0 and were followed monthly for 1 year. Injections were repeated monthly if persistent or new cystic edema manifested on optical coherence tomography. The primary outcome measure was the mean change in best-corrected visual acuity from baseline at 12 months. Secondary outcome measures included mean percentage change in central subfield retinal thickness (CST) and incidence of adverse events through Month 24.

Results: Thirty-two injections were performed over the study period. At 1 year, the mean increase in acuity was 12.2 Early Treatment for Diabetic Retinopathy Study letters (P = 0.015). There was a statistically significant increase in visual acuity over time (P = 0.002). The CST decreased by 31.4%, 46.0%, 37.6%, and 45.4% relative to baseline at 3, 6, 9, and 12 months, respectively (P = 0.003). One patient experienced recurrence of uveitis with subsequent cataract and glaucoma progression.

Conclusion: Optical coherence tomography-guided monthly intravitreal ranibizumab injections delivered over the course of 1 year resulted in improved vision and reduced central retinal thickness.

Original languageEnglish
Pages (from-to)2431-2438
Number of pages8
JournalRetina
Volume34
Issue number12
StatePublished - Jan 1 2014

Fingerprint

Macular Edema
Uveitis
Optical Coherence Tomography
Intravitreal Injections
Injections
Visual Acuity
Outcome Assessment (Health Care)
Low Vision
Diabetic Retinopathy
Glaucoma
Cataract
Edema
Therapeutics
Recurrence
Incidence
Ranibizumab

Keywords

  • Anti-vascular endothelial growth factor
  • Antiangiogenics
  • Cystoid macular edema
  • Ranibizumab
  • Uveitic macular edema
  • Uveitis

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Optical coherence tomography-guided ranibizumab injection for cystoid macular edema in well-controlled uveitis : Twelve-month outcomes. / Reddy, Ashvini K.; Cabrera, Mariana; Yeh, Steven; Davis, Janet L; Albini, Thomas A.

In: Retina, Vol. 34, No. 12, 01.01.2014, p. 2431-2438.

Research output: Contribution to journalArticle

@article{dd4dc7b9c2a74c4284114b715ba0fab6,
title = "Optical coherence tomography-guided ranibizumab injection for cystoid macular edema in well-controlled uveitis: Twelve-month outcomes",
abstract = "Purpose: To determine whether serial ranibizumab injections are effective in the treatment of cystoid macular edema in patients with chronic controlled noninfectious uveitis.Methods: Five eyes of 5 patients were included in a prospective noncomparative therapeutic trial. They received intravitreal injections of ranibizumab at Day 0 and were followed monthly for 1 year. Injections were repeated monthly if persistent or new cystic edema manifested on optical coherence tomography. The primary outcome measure was the mean change in best-corrected visual acuity from baseline at 12 months. Secondary outcome measures included mean percentage change in central subfield retinal thickness (CST) and incidence of adverse events through Month 24.Results: Thirty-two injections were performed over the study period. At 1 year, the mean increase in acuity was 12.2 Early Treatment for Diabetic Retinopathy Study letters (P = 0.015). There was a statistically significant increase in visual acuity over time (P = 0.002). The CST decreased by 31.4{\%}, 46.0{\%}, 37.6{\%}, and 45.4{\%} relative to baseline at 3, 6, 9, and 12 months, respectively (P = 0.003). One patient experienced recurrence of uveitis with subsequent cataract and glaucoma progression.Conclusion: Optical coherence tomography-guided monthly intravitreal ranibizumab injections delivered over the course of 1 year resulted in improved vision and reduced central retinal thickness.",
keywords = "Anti-vascular endothelial growth factor, Antiangiogenics, Cystoid macular edema, Ranibizumab, Uveitic macular edema, Uveitis",
author = "Reddy, {Ashvini K.} and Mariana Cabrera and Steven Yeh and Davis, {Janet L} and Albini, {Thomas A}",
year = "2014",
month = "1",
day = "1",
language = "English",
volume = "34",
pages = "2431--2438",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Optical coherence tomography-guided ranibizumab injection for cystoid macular edema in well-controlled uveitis

T2 - Twelve-month outcomes

AU - Reddy, Ashvini K.

AU - Cabrera, Mariana

AU - Yeh, Steven

AU - Davis, Janet L

AU - Albini, Thomas A

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Purpose: To determine whether serial ranibizumab injections are effective in the treatment of cystoid macular edema in patients with chronic controlled noninfectious uveitis.Methods: Five eyes of 5 patients were included in a prospective noncomparative therapeutic trial. They received intravitreal injections of ranibizumab at Day 0 and were followed monthly for 1 year. Injections were repeated monthly if persistent or new cystic edema manifested on optical coherence tomography. The primary outcome measure was the mean change in best-corrected visual acuity from baseline at 12 months. Secondary outcome measures included mean percentage change in central subfield retinal thickness (CST) and incidence of adverse events through Month 24.Results: Thirty-two injections were performed over the study period. At 1 year, the mean increase in acuity was 12.2 Early Treatment for Diabetic Retinopathy Study letters (P = 0.015). There was a statistically significant increase in visual acuity over time (P = 0.002). The CST decreased by 31.4%, 46.0%, 37.6%, and 45.4% relative to baseline at 3, 6, 9, and 12 months, respectively (P = 0.003). One patient experienced recurrence of uveitis with subsequent cataract and glaucoma progression.Conclusion: Optical coherence tomography-guided monthly intravitreal ranibizumab injections delivered over the course of 1 year resulted in improved vision and reduced central retinal thickness.

AB - Purpose: To determine whether serial ranibizumab injections are effective in the treatment of cystoid macular edema in patients with chronic controlled noninfectious uveitis.Methods: Five eyes of 5 patients were included in a prospective noncomparative therapeutic trial. They received intravitreal injections of ranibizumab at Day 0 and were followed monthly for 1 year. Injections were repeated monthly if persistent or new cystic edema manifested on optical coherence tomography. The primary outcome measure was the mean change in best-corrected visual acuity from baseline at 12 months. Secondary outcome measures included mean percentage change in central subfield retinal thickness (CST) and incidence of adverse events through Month 24.Results: Thirty-two injections were performed over the study period. At 1 year, the mean increase in acuity was 12.2 Early Treatment for Diabetic Retinopathy Study letters (P = 0.015). There was a statistically significant increase in visual acuity over time (P = 0.002). The CST decreased by 31.4%, 46.0%, 37.6%, and 45.4% relative to baseline at 3, 6, 9, and 12 months, respectively (P = 0.003). One patient experienced recurrence of uveitis with subsequent cataract and glaucoma progression.Conclusion: Optical coherence tomography-guided monthly intravitreal ranibizumab injections delivered over the course of 1 year resulted in improved vision and reduced central retinal thickness.

KW - Anti-vascular endothelial growth factor

KW - Antiangiogenics

KW - Cystoid macular edema

KW - Ranibizumab

KW - Uveitic macular edema

KW - Uveitis

UR - http://www.scopus.com/inward/record.url?scp=84916641120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84916641120&partnerID=8YFLogxK

M3 - Article

C2 - 25170857

AN - SCOPUS:84916641120

VL - 34

SP - 2431

EP - 2438

JO - Retina

JF - Retina

SN - 0275-004X

IS - 12

ER -